Issue #3 — Theranos: The Board That Was Built Not To Ask
Theranos had one of the most prestigious boards in America, and one of the least effective. A study of how the board’s missing oversight enabled the fraud, and what it teaches about building boards that verify rather than vouch.
The New Board Question: “What’s Our Exposure to AI‑Driven Misconduct?”
Two companies, same AI tools, totally different risk profiles. Daniel Santos on the new board question — “What’s our exposure to AI-driven misconduct?” — and why AI accountability, not technology, decides whether your governance holds up under scrutiny.